Based in Cambridge, UK, Ario Pharma is a spin out from Xention Pharma, a specialist ion channel R&D company, and its scientific advisory board is comprised of world-renowned UK experts in respiratory disease.

Ario aims to evaluate the anti-tussive properties of XEN-D0501, a potential best-in-class TRPV1 inhibitor, in two Phase II clinical trials that will read out in 2014. XEN-D0501 has successfully completed multiple Phase I studies and has been shown to be safe and well tolerated.